IRVINE, CA--(Marketwired - Oct 17, 2013) - Masimo (
At Stanford University Medical School in Menlo Park, Calif., researchers evaluated RRa and capnography during sedation. The investigators reported: "Of the respiratory pauses detected by a single method, acoustic monitoring had the highest percentage of true positives and the lowest percentage of false positives." They concluded: "When compared to clinical observation or capnography, rainbow® acoustic monitoring (RAM) may provide the best method for detection of respiratory pause during procedures requiring sedation because it has acceptable accuracy for detection of respiratory pause with a low rate of false alarms."1
At Loma Linda University Medical Center in Loma Linda, Calif., researchers found that compared to nasal cannula capnometry (Covidien Capnostream® 20), RAM RRa "detected more true events and had fewer false alarms," adding, "Compared to nasal cannula capnometry, acoustic respiratory monitoring may be a superior monitor of respiration during procedural sedation."2
At Tokyo Women's Medical University, School of Medicine, in Tokyo, Japan, researchers evaluated RAM (RRa), capnometry (CAP), and thoracic impedance pneumography (IMP) and compared them with visual 1-minute chest movement inspection. Investigators concluded: "Continuous respiration rate assessments with RRa correlated well with visual inspection, even for obese patients and patients with respiration rate ≤10 per minute. CAP measurements also showed good correlation with visual chest movement inspection, but the equipment was often removed by some patients because of displeasure or an inserted gastric tube. IMP measurements were inaccurate because of electrode positioning and patient movement and shivering. Therefore, RRa was the most accurate and noninvasive method to monitor respiration rate for detecting apnea, bradypnea, and airway obstruction."3
PVI® with Masimo SET® Pulse Oximetry
At University of California Irvine Medical Center in Irvine, Calif., researchers evaluated whether goal-directed fluid optimization based on PVI can be used reliably intra-operatively in patients undergoing moderate-risk surgery. Investigators concluded, "Goal-directed fluid optimization based on respiratory variation in the pulse oximeter waveform is feasible, and may help to standardize intraoperative fluid management."4
1 Tanaka P, Drover D, Tanaka M. "Detection of Respiratory Pauses by Clinical Observation: Capnography and Acoustic Monitoring" Proceedings of the American Society of Anesthesiologists, October 16, 2013. San Francisco. A5033
2 Applegate R, Lenart J, Malkin M, Macknet M. "Respiratory Pause Detection and False Alarms from Capnography and Acoustic Monitoring in Procedure Related Sedation" Proceedings of the American Society of Anesthesiologists, October 16, 2013. San Francisco. A5027
3 Fukada T, Uenaka Y, Tsuchiya Y, Iwakiri H, Nomura M. "Clinical Evaluation on Acoustic Respiration Rate (RRa™) in PACU Compared With the Conventional Monitoring System" Proceedings of the American Society of Anesthesiologists, October 12, 2013. San Francisco. A1180
4 Canales C, Lee C, Khanh-Van L, Hanacek C, Natalia N, Nguyen C, Le A, Boud R, Rinehart J, Cannesson M. "Feasibility of Goal-Directed Fluid Management Based on Monitoring of Pleth Variability Index (PVI)" Proceedings of the American Society of Anesthesiologists, October 13, 2013. San Francisco. A2211
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®), PVI®, and acoustic respiration rate (RRa™) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SeDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.